Navigation Links
Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
Date:11/9/2010

vaccine being produced for the U.S. military. U.S. military sales in 2010 depend on further use of residual product stock of JE-Vax®. A significant increase in sales is possible for 2011, when leftover inventory of JE-Vax is expected to be exhausted or abandoned.

The Department of Health, Government of the Hong Kong Special Administrative Regions has approved Intercell's vaccine to prevent Japanese Encephalitis. The licensure process has been initiated for additional territories, and further recommendations are expected also for other key countries in Europe. These recommendations are essential to continue advancing product awareness and market growth.

The pediatric Phase III studies for IXIARO/JESPECT for use in children travelling to endemic areas are progressing according to plan, with data expected in 2012. These studies are the basis for a label extension to make the existing vaccine available for travelling children.

Based on Intercell's technology a novel JE vaccine candidate is also being developed for the endemic markets, where the WHO recommends that Japanese Encephalitis vaccination be integrated into national immunization programs. Clinical development in endemic areas is progressing, with a pivotal Phase III trial in children scheduled to start by the end of 2010 / early 2011 sponsored and managed by Intercell's partner, Biological E., in India.

Leading R&D portfolio in hospital infectionsA Phase II clinical trial involving IC43, the vaccine candidate against infections with the bacterium Pseudomonas aeruginosa, met primary immunogenicity and safety endpoints; a statistically significant reduction in mortality compared to placebo was observed for the non-adjuvanted vaccine group. If confirmed by pivotal clinical trials, this could make IC43 an important vaccine for ICU patients who are subject to a particularly high mortality risk associated with hospital-acquired infections. The vaccine generated a good immune r
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
2. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
3. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
4. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
5. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
6. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
7. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
8. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
9. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
11. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... pleased to announce first quarter 2012 revenues of $210,635, ... The increase in revenues was driven by surgeries at ... using the Kelyniam Custom Skull Implant made from PEEK ... quarter with the new management and a full sales ...
... SNDY) is pleased to announce that the Company has successfully ... $570,000.  As a result, the Company expects to achieve a ... financials, and show significant reduction of its liabilities for the ... issued Preferred Stock valued at $10 per share in order ...
Cached Medicine Technology:Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012 2Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012 3Solos Endoscopy Reduces Liabilities by More than $570,000 2Solos Endoscopy Reduces Liabilities by More than $570,000 3
(Date:7/12/2014)... York, NY (PRWEB) July 12, 2014 ... steady growth over the past five years, buoyed by ... agricultural sector's supply management system. “Eggs are a relatively ... result, per capita egg consumption generally grows in line ... Industry Analyst Will McKitterick. Furthermore, demand for new specialty ...
(Date:7/12/2014)... 2014 The rise in the number ... new advanced network architectures to suit the upsurge. Virtualization ... with increasing cloud storage technologies. The data traffic has ... mobility devices. This has resulted in larger and more ... forces for the SDN market. , The North American ...
(Date:7/12/2014)... The "North American ... Market by Angioplasty Balloon (Plain/Old, Cutting), ... IVC Filter (Retrievable), Endovascular Stent Graft ... studies the major market drivers, restraints, ... Canada. , Browse 108 market data ...
(Date:7/12/2014)... The Security Analytics market is estimated to ... by 2019, at an expected CAGR of 9.7% for ... counter the increasing number of security breaches, continued line ... systems in organizations are enormous. Vendors in the security ... architecture to develop better and more secure systems. , ...
(Date:7/12/2014)... Melbourne, Australia (PRWEB) July 12, 2014 ... past five years, despite rising competition from international and ... compound annual 2.9% over the five years through 2014-15. ... with consumers demanding more gaming services. Rises in discretionary ... have spent more money on non-essential items such as ...
Breaking Medicine News(10 mins):Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4
... Failure by Sutter Medical Center Santa Rosa and Santa ... of county services fuels efforts to make ... SANTA ROSA, Calif., March 12 In the ... workers,at Santa Rosa Memorial Hospital -- already engaged in ...
... show whether an antidepressant is working , , TUESDAY, March ... biomarker for depression that could lead to a quick ... making headway against the disease. , "This may be ... co-author Mark Rasenick, director of the Interdisciplinary Neuroscience Program ...
... study in the,Journal of the American Medical Association ... Staphylococus aureus), a simple,skin or nasal swab, is ... for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and Nosocomial ... March 12, 2008)., The findings of the ...
... (NYSE:,WLP) announced today that senior management is scheduled to present at ... Healthcare Conference on March 13, 2008, ... Daylight Time (EDT);, -- Lehman Brothers ... March 19, 2008, at 10:15 a.m. EDT., All interested parties ...
... a good news, bad news situation. Some women who ... dont have cancer, they do have atypical hyperplasia -- ... someday. This happens to one-fourth of women undergoing breast ... risk. , In their quest to discover who is ...
... Zimmer Holdings, Inc.,(NYSE ZMH; SWX: ZMH), a leader in the ... upcoming investor,conferences:, -- March 18, 2008 -- Cowen,s ... Massachusetts, 8:00 a.m. Eastern Time -- March 19, 2008 ... Conference, Miami Beach, Florida, 8:30 a.m. Eastern Time, ...
Cached Medicine News:Health News:Santa Rosa Healthcare Workers Seek Accountability From Catholic Hospital System 2Health News:Scientists Spot Biochemical Sign of Depression 2Health News:Scientists Spot Biochemical Sign of Depression 3Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 2Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 3Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 4
The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
The new XVG catheter is our highest power thrombectomy catheter designed for accessing distal anatomy. Utilizing proprietary Cross-Stream water jet technology, the XVG catheter removes thrombus quick...
Redel Connector 10 Pin...
... a non-fluoroscopic navigation system that tracks multiple ... Fred Wittkampf, Ph.D., and is being developed ... ,The LocaLisa system uses three ... around the heart to track catheters. Using ...
Medicine Products: